Painting a picture of the melanoma clinical trial participant: Underscoring the key factors that drive melanoma patients to participate in clinical trials [whitepaper]
In 2018, Antidote and SCORR Marketing worked with eight leading health organizations, including the Melanoma Research Alliance, to survey 4,000 patients about clinical research. About 10% of the total respondents self-identified as having melanoma.
In this whitepaper, we explore what matters most to melanoma patients when it comes to participating in clinical trials, including:
participating in research for potential new treatments;
trusted doctors and clinical staff who are willing to answer questions throughout the process;
support from friends and family; and
access to care at large academic medical centers or a community oncologist affiliated with a cancer center.